HRP20120335T1 - 2,4-pirimidindiamini korisni za liječenje neoplastičnih bolesti, upala i poremećaja imunološkog sustava - Google Patents

2,4-pirimidindiamini korisni za liječenje neoplastičnih bolesti, upala i poremećaja imunološkog sustava Download PDF

Info

Publication number: HRP20120335T1
Authority: HR; Croatia
Prior art keywords: methyl; ethyl; amino; following; sulfamoyl
Prior art date: 2003-08-15

Application number

HRP20120335TT

Other languages

English (en)

Croatian (hr)

Inventor

Garcia-Echeverria Carlos

Kanazawa Takanori

Kawahara Eiji

Masuya Keiichi

Matsuura Naoko

Miyake Takahiro

Ohmori Osamu

Umemura Ichiro

Steensma Ruo

Chopiuk Greg

Jiang Jiqing

Wan Yongqin

Ding Qiang

Zhang Qiong

Schiander Gray Nathanael

Karanewsky Donald

Original Assignee

Novartis Ag

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-15

Filing date

2012-04-16

Publication date

2012-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34196260&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120335(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-15 Priority claimed from GB0319227A external-priority patent/GB0319227D0/en

2003-09-24 Priority claimed from GB0322370A external-priority patent/GB0322370D0/en

2012-04-16 Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag

2012-05-31 Publication of HRP20120335T1 publication Critical patent/HRP20120335T1/hr

Links

201000010099 disease Diseases 0.000 title claims 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 6
208000026278 immune system disease Diseases 0.000 title claims 4
208000027866 inflammatory disease Diseases 0.000 title claims 3
230000002757 inflammatory effect Effects 0.000 title claims 3
230000001613 neoplastic effect Effects 0.000 title claims 3
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
-1 ethoxy, ethyl Chemical group 0.000 claims abstract 33
150000001875 compounds Chemical class 0.000 claims abstract 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
239000001257 hydrogen Substances 0.000 claims abstract 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 5
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims abstract 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 4
125000003386 piperidinyl group Chemical group 0.000 claims abstract 4
125000001475 halogen functional group Chemical group 0.000 claims abstract 3
125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims abstract 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims abstract 2
239000005977 Ethylene Substances 0.000 claims abstract 2
LIWAQLJGPBVORC-UHFFFAOYSA-N N-ethyl-N-methylamine Chemical group CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims abstract 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract 2
IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical group CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 claims abstract 2
150000002431 hydrogen Chemical class 0.000 claims abstract 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 2
NULJZZQMTQVLPG-UHFFFAOYSA-N n,n-dimethylmorpholin-4-amine Chemical group CN(C)N1CCOCC1 NULJZZQMTQVLPG-UHFFFAOYSA-N 0.000 claims abstract 2
150000002825 nitriles Chemical class 0.000 claims abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
125000004193 piperazinyl group Chemical group 0.000 claims abstract 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 2
125000003226 pyrazolyl group Chemical group 0.000 claims abstract 2
125000004076 pyridyl group Chemical group 0.000 claims abstract 2
125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 2
239000003814 drug Substances 0.000 claims 3
229940079593 drug Drugs 0.000 claims 3
230000002265 prevention Effects 0.000 claims 3
230000002062 proliferating effect Effects 0.000 claims 3
150000003839 salts Chemical class 0.000 claims 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
208000037765 diseases and disorders Diseases 0.000 claims 2
210000000987 immune system Anatomy 0.000 claims 2
208000023275 Autoimmune disease Diseases 0.000 claims 1
208000026310 Breast neoplasm Diseases 0.000 claims 1
208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
206010020751 Hypersensitivity Diseases 0.000 claims 1
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
206010061535 Ovarian neoplasm Diseases 0.000 claims 1
206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
210000001744 T-lymphocyte Anatomy 0.000 claims 1
208000024770 Thyroid neoplasm Diseases 0.000 claims 1
206010052779 Transplant rejections Diseases 0.000 claims 1
102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 claims 1
108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
208000026935 allergic disease Diseases 0.000 claims 1
230000007815 allergy Effects 0.000 claims 1
210000003719 b-lymphocyte Anatomy 0.000 claims 1
210000000481 breast Anatomy 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
210000004443 dendritic cell Anatomy 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
230000006806 disease prevention Effects 0.000 claims 1
210000003979 eosinophil Anatomy 0.000 claims 1
125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims 1
210000003630 histaminocyte Anatomy 0.000 claims 1
210000002865 immune cell Anatomy 0.000 claims 1
230000005764 inhibitory process Effects 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
208000037841 lung tumor Diseases 0.000 claims 1
210000002540 macrophage Anatomy 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
239000012907 medicinal substance Substances 0.000 claims 1
201000001441 melanoma Diseases 0.000 claims 1
230000001537 neural effect Effects 0.000 claims 1
208000014500 neuronal tumor Diseases 0.000 claims 1
201000008968 osteosarcoma Diseases 0.000 claims 1
230000002611 ovarian Effects 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
210000002307 prostate Anatomy 0.000 claims 1
208000023958 prostate neoplasm Diseases 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
210000001685 thyroid gland Anatomy 0.000 claims 1
208000013076 thyroid tumor Diseases 0.000 claims 1
208000025421 tumor of uterus Diseases 0.000 claims 1
206010046766 uterine cancer Diseases 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

HRP20120335TT 2003-08-15 2012-04-16 2,4-pirimidindiamini korisni za liječenje neoplastičnih bolesti, upala i poremećaja imunološkog sustava HRP20120335T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0319227A GB0319227D0 (en)	2003-08-15	2003-08-15	Organic compounds
GB0322370A GB0322370D0 (en)	2003-09-24	2003-09-24	Organic compounds
PCT/EP2004/009099 WO2005016894A1 (en)	2003-08-15	2004-08-13	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Publications (1)

Publication Number	Publication Date
HRP20120335T1 true HRP20120335T1 (hr)	2012-05-31

Family

ID=34196260

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HRP20120335TT HRP20120335T1 (hr)	2003-08-15	2012-04-16	2,4-pirimidindiamini korisni za liječenje neoplastičnih bolesti, upala i poremećaja imunološkog sustava
HRP20130724TT HRP20130724T1 (hr)	2003-08-15	2013-08-01	2,4-di(fenilamino)-pirimidini korisni u lijeäśenju neoplastiäśnih bolesti, upalnih poremeä†aja i poremeä†aja imunološkog sustava

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HRP20130724TT HRP20130724T1 (hr)	2003-08-15	2013-08-01	2,4-di(fenilamino)-pirimidini korisni u lijeäśenju neoplastiäśnih bolesti, upalnih poremeä†aja i poremeä†aja imunološkog sustava

Country Status (32)

Country	Link
US (2)	US7893074B2 (is)
EP (2)	EP2287156B1 (is)
JP (2)	JP4607879B2 (is)
KR (1)	KR100904570B1 (is)
AR (1)	AR045458A1 (is)
AT (1)	ATE542801T1 (is)
AU (2)	AU2004264382A1 (is)
BR (2)	BRPI0413616B8 (is)
CA (1)	CA2533320A1 (is)
CO (1)	CO5680434A2 (is)
CY (2)	CY1112571T1 (is)
DK (2)	DK1660458T3 (is)
EC (1)	ECSP066371A (is)
ES (2)	ES2380206T3 (is)
HK (1)	HK1091813A1 (is)
HR (2)	HRP20120335T1 (is)
IL (1)	IL173129A0 (is)
IS (1)	IS2873B (is)
MA (1)	MA27994A1 (is)
MX (1)	MXPA06001759A (is)
MY (1)	MY147449A (is)
NO (1)	NO333306B1 (is)
NZ (1)	NZ585188A (is)
PL (2)	PL2287156T3 (is)
PT (2)	PT2287156E (is)
RU (1)	RU2395500C2 (is)
SG (1)	SG145749A1 (is)
SI (2)	SI2287156T1 (is)
TN (1)	TNSN06052A1 (is)
TW (1)	TWI378923B (is)
WO (1)	WO2005016894A1 (is)
ZA (1)	ZA200600464B (is)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
ATE451104T1 (de)	2002-07-29	2009-12-15	Rigel Pharmaceuticals Inc	Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
EP1599468B1 (en)	2003-01-14	2007-10-03	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
JP2004313181A (ja) *	2003-04-02	2004-11-11	Canon Inc	感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
CN1849318B (zh)	2003-07-30	2011-10-12	里格尔药品股份有限公司	用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
SG145749A1 (en) *	2003-08-15	2008-09-29	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US8131475B2 (en) *	2003-09-03	2012-03-06	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1809614B1 (en)	2004-04-08	2014-05-07	TargeGen, Inc.	Benzotriazine inhibitors of kinases
EP1598343A1 (de) *	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) *	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
PL382308A1 (pl)	2004-08-25	2007-08-20	Targegen, Inc.	Związki heterocykliczne i sposoby stosowania
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
BRPI0606318B8 (pt)	2005-01-19	2021-05-25	Rigel Pharmaceuticals Inc	composto, composição, e, uso de um composto
KR101312225B1 (ko)	2005-06-08	2013-09-26	리겔 파마슈티칼스, 인크.	Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2007028445A1 (en) *	2005-07-15	2007-03-15	Glaxo Group Limited	6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
TW200740805A (en) *	2005-07-15	2007-11-01	Glaxo Group Ltd	Novel compounds
GB0517329D0 (en) *	2005-08-25	2005-10-05	Merck Sharp & Dohme	Stimulation of neurogenesis
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011787B1 (pt) *	2005-11-01	2022-01-25	Impact Biomedicines, Inc	Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
TW200736232A (en) *	2006-01-26	2007-10-01	Astrazeneca Ab	Pyrimidine derivatives
WO2007085540A1 (en) *	2006-01-27	2007-08-02	Glaxo Group Limited	1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
PT1984357E (pt)	2006-02-17	2013-12-23	Rigel Pharmaceuticals Inc	Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
US8168383B2 (en)	2006-04-14	2012-05-01	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
SI2450437T1 (sl)	2006-04-14	2017-12-29	Cell Signaling Technology Inc.	Okvarjenost genov in mutantna ALK kinaza v človeških solidnih tumorjih
CA2598893C (en)	2006-10-11	2012-04-10	Astellas Pharma Inc.	Eml4-alk fusion gene
EP1914240B1 (en)	2006-10-11	2009-12-02	Astellas Pharma Inc.	EML4-ALK fusion gene
EP2684874B1 (en)	2006-10-23	2017-05-17	Cephalon, Inc.	Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors
PL2091918T3 (pl) *	2006-12-08	2015-02-27	Novartis Ag	Związki i kompozycje jako inhibitory kinazy białkowej
KR101364277B1 (ko) *	2006-12-08	2014-02-21	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물
CA2670645A1 (en) *	2006-12-19	2008-07-03	Genentech, Inc.	Pyrimidine kinase inhibitors
AR065015A1 (es)	2007-01-26	2009-05-13	Smithkline Beecham Corp	Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
WO2008129380A1 (en)	2007-04-18	2008-10-30	Pfizer Products Inc.	Sulfonyl amide derivatives for the treatment of abnormal cell growth
TWI389893B (zh) *	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物
EP2183242A2 (en) *	2007-07-16	2010-05-12	AstraZeneca AB	Pyrimidine derivatives 934
CN101827848B (zh) *	2007-08-08	2012-11-07	葛兰素史密丝克莱恩有限责任公司	作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
EA017252B1 (ru) *	2007-08-28	2012-11-30	Айрм Ллк	Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
AU2008296479A1 (en) *	2007-08-28	2009-03-12	Dana Farber Cancer Institute	Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009080638A2 (en)	2007-12-20	2009-07-02	Cellzome Limited	Sulfamides as zap-70 inhibitors
WO2009105498A1 (en) *	2008-02-19	2009-08-27	Smithkline Beecham Corporation	Anilinopyridines as inhibitors of fak
EA018282B1 (ru) *	2008-04-07	2013-06-28	Айрм Ллк	Соединения и композиции в качестве ингибиторов протеинкиназы
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
NZ589315A (en)	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
WO2009136995A2 (en)	2008-04-16	2009-11-12	Portola Pharmaceuticals, Inc.	Inhibitors of syk protein kinase
CA2723185A1 (en)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
DK2300013T3 (en) *	2008-05-21	2017-12-04	Ariad Pharma Inc	PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
US8569298B2 (en) *	2008-06-17	2013-10-29	Astrazeneca Ab	Pyridine compounds
UY31929A (es)	2008-06-25	2010-01-05	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) *	2008-06-27	2011-03-09	아빌라 테라퓨틱스, 인크.	헤테로아릴 화합물 및 이의 용도
JO3067B1 (ar) *	2008-10-27	2017-03-15	Glaxosmithkline Llc	بيرميدينات بيرازولو امينو كمثبطات ل fak
AR074209A1 (es)	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh)	2008-11-24	2015-07-11	Boehringer Ingelheim Int	新穎化合物
ES2539620T3 (es)	2008-12-19	2015-07-02	Cephalon, Inc.	Pirrolotriazina como inhibidor de ALK y de JAK2
NZ594323A (en)	2009-01-23	2013-05-31	Rigel Pharmaceuticals Inc	Compositions and methods for inhibition of the jak pathway
WO2010112210A1 (en)	2009-04-03	2010-10-07	Cellzome Ag	Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
US20120040955A1 (en)	2009-04-14	2012-02-16	Richard John Harrison	Fluoro substituted pyrimidine compounds as jak3 inhibitors
WO2010129053A2 (en)	2009-05-05	2010-11-11	Dana Farber Cancer Institute	Egfr inhibitors and methods of treating disorders
TW201100441A (en) *	2009-06-01	2011-01-01	Osi Pharm Inc	Amino pyrimidine anticancer compounds
WO2010144468A1 (en) *	2009-06-10	2010-12-16	Abbott Laboratories	2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
US20120142667A1 (en) *	2009-06-10	2012-06-07	Nigel Ramsden	Pyrimidine derivatives as zap-70 inhibitors
US8765747B2 (en)	2009-06-12	2014-07-01	Dana-Farber Cancer Institute, Inc.	Fused 2-aminothiazole compounds
CA2763730A1 (en) *	2009-06-18	2010-12-23	Cellzome Limited	Heterocyclylaminopyrimidines as kinase inhibitors
EP2443095A1 (en) *	2009-06-18	2012-04-25	Cellzome Limited	Sulfonamides and sulfamides as zap-70 inhibitors
EP2475648A1 (en) *	2009-09-11	2012-07-18	Cellzome Limited	Ortho substituted pyrimidine compounds as jak inhibitors
WO2011140338A1 (en) *	2010-05-05	2011-11-10	Gatekeeper Pharmaceuticals, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
CA2798578C (en)	2010-05-21	2015-12-29	Chemilia Ab	Novel pyrimidine derivatives
WO2012019132A2 (en)	2010-08-06	2012-02-09	Cell Signaling Technology, Inc.	Anaplastic lymphoma kinase in kidney cancer
CA2807051A1 (en)	2010-08-10	2012-02-16	Celgene Avilomics Research, Inc.	Besylate salt of a btk inhibitor
AU2011305525B2 (en)	2010-09-22	2016-08-18	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
TWI545115B (zh) *	2010-11-01	2016-08-11	阿維拉製藥公司	雜環化合物及其用途
US9102625B2 (en)	2010-11-01	2015-08-11	Portola Pharmaceuticals, Inc.	Nicotinamides as JAK kinase modulators
US20130317029A1 (en)	2010-11-01	2013-11-28	Portola Pharmaceuticals, Inc.	Oxypyrimidines as syk modulators
US8846928B2 (en)	2010-11-01	2014-09-30	Portola Pharmaceuticals, Inc.	Benzamides and nicotinamides as Syk modulators
ES2635713T3 (es)	2010-11-01	2017-10-04	Celgene Car Llc	Compuestos de heteroarilo y usos de los mismos
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
JP5957003B2 (ja)	2010-11-10	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	変異体選択的ｅｇｆｒ阻害剤およびその使用
EP2646448B1 (en)	2010-11-29	2017-08-30	OSI Pharmaceuticals, LLC	Macrocyclic kinase inhibitors
CN112125884A (zh) *	2010-12-17	2020-12-25	诺华股份有限公司	制备嘧啶-2,4-二胺二盐酸盐的方法
US8546443B2 (en)	2010-12-21	2013-10-01	Boehringer Ingelheim International Gmbh	Benzylic oxindole pyrimidines
JP2012153674A (ja)	2011-01-28	2012-08-16	Astellas Pharma Inc	ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
EP2670401B1 (en) *	2011-02-02	2015-06-10	Novartis AG	Methods of using alk inhibitors
CN103534240B (zh)	2011-02-17	2015-12-09	癌症疗法Crc私人有限公司	选择性fak抑制剂
EP2675793B1 (en)	2011-02-17	2018-08-08	Cancer Therapeutics Crc Pty Limited	Fak inhibitors
CA2830129C (en)	2011-03-24	2016-07-19	Chemilia Ab	Novel pyrimidine derivatives
US9249124B2 (en)	2011-03-30	2016-02-02	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase inhibitors and methods of making and using thereof
RU2697712C2 (ru)	2011-04-22	2019-08-19	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
CN103501612B (zh)	2011-05-04	2017-03-29	阿里亚德医药股份有限公司	抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
EP2770830A4 (en)	2011-10-28	2015-05-27	Celgene Avilomics Res Inc	METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
EP3569598A1 (en)	2011-11-17	2019-11-20	Dana Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
EP2782579B1 (en)	2011-11-23	2019-01-02	Portola Pharmaceuticals, Inc.	Pyrazine kinase inhibitors
NZ630251A (en)	2012-03-06	2016-02-26	Cephalon Inc	Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
JP6317320B2 (ja)	2012-03-15	2018-04-25	セルジーンシーエーアールエルエルシー	上皮成長因子受容体キナーゼ阻害剤の塩
CN108658873B (zh)	2012-03-15	2021-09-14	西建卡尔有限责任公司	表皮生长因子受体激酶抑制剂的固体形式
US20150166591A1 (en)	2012-05-05	2015-06-18	Ariad Pharmaceuticals, Inc.	Methods and compositions for raf kinase mediated diseases
KR101582852B1 (ko)	2012-05-24	2016-01-07	서울대학교 산학협력단	타우 단백질 매개 신경 퇴행성 질환 치료제
KR101446742B1 (ko)	2012-08-10	2014-10-01	한국화학연구원	Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US9676756B2 (en)	2012-10-08	2017-06-13	Portola Pharmaceuticals, Inc.	Substituted pyrimidinyl kinase inhibitors
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
EP4223770A3 (en)	2012-11-05	2023-10-18	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
CN104854101B (zh) *	2012-11-06	2018-05-01	上海复尚慧创医药研究有限公司	Alk激酶抑制剂
CN103804299A (zh) *	2012-11-14	2014-05-21	韩冰	一类具有神经保护作用的化合物及其用途
EP2935226A4 (en)	2012-12-21	2016-11-02	Celgene Avilomics Res Inc	HETEROARYL COMPOUNDS AND USES THEREOF
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
CN105188371A (zh)	2013-02-08	2015-12-23	西建阿维拉米斯研究公司	Erk抑制剂及其用途
WO2014128235A1 (en)	2013-02-22	2014-08-28	F. Hoffmann-La Roche Ag	Methods of treating cancer and preventing drug resistance
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014193932A1 (en)	2013-05-29	2014-12-04	Cephalon, Inc.	Pyrrolotriazines as alk inhibitors
BR112015030578A2 (pt)	2013-06-18	2017-07-25	Novartis Ag	combinações farmacêuticas
US9783524B2 (en)	2013-07-11	2017-10-10	Betta Pharmaceuticals Co., Ltd.	Protein tyrosine kinase modulators and methods of use
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015038868A1 (en) *	2013-09-13	2015-03-19	Cephalon, Inc.	Fused bicyclic 2,4-diaminopyrimidine derivatives
RU2550346C2 (ru)	2013-09-26	2015-05-10	Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех"	Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
ES2676734T3 (es)	2013-10-18	2018-07-24	Syros Pharmaceuticals, Inc.	Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
AU2014346788B8 (en)	2013-11-06	2021-01-28	Arizona Board Of Regents On Behalf Of The Unviersity Of Arizona	Method for subtyping lymphoma types by means of expression profiling
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) *	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
US10005760B2 (en)	2014-08-13	2018-06-26	Celgene Car Llc	Forms and compositions of an ERK inhibitor
WO2016029002A2 (en) *	2014-08-22	2016-02-25	Clovis Oncology, Inc.	Growth factor receptor inhibitors
LT3209647T (lt)	2014-10-21	2020-09-25	Ariad Pharmaceuticals, Inc.	Kristalinės 5-chlor-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il) piperidin-1-il]pirimidin-2,4-diamino formos
WO2016100308A1 (en)	2014-12-16	2016-06-23	Signal Pharmaceuticals, Llc	Methods for measurement of inhibition of c-jun n-terminal kinase in skin
ES2877642T3 (es)	2014-12-16	2021-11-17	Signal Pharm Llc	Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
JP6854762B2 (ja)	2014-12-23	2021-04-07	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
MX2021011472A (es)	2015-01-06	2022-08-17	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
CA2975260A1 (en)	2015-01-29	2016-08-04	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6861166B2 (ja)	2015-03-27	2021-04-21	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼの阻害剤
WO2016167511A2 (ko) *	2015-04-14	2016-10-20	한국화학연구원	N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2016276963C1 (en)	2015-06-12	2021-08-05	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
PL3310760T3 (pl)	2015-06-22	2023-03-06	Arena Pharmaceuticals, Inc.	Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
MX2018001004A (es)	2015-07-24	2018-06-07	Celgene Corp	Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
CA2996978A1 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
CN106699743B (zh) *	2015-11-05	2020-06-12	湖北生物医药产业技术研究院有限公司	嘧啶类衍生物及其用途
CN106883213B (zh) *	2015-12-15	2021-04-20	合肥中科普瑞昇生物医药科技有限公司	一种egfr和alk激酶的双重抑制剂
EP3476848A4 (en) *	2016-06-27	2020-01-15	Hangzhou Rex Pharmaceutical Co., Ltd	BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR
EP4001273A3 (en)	2016-08-29	2022-08-24	The Regents Of The University Of Michigan	Aminopyrimidines as alk inhibitors
KR101876514B1 (ko)	2016-11-08	2018-07-10	한국화학연구원	신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
WO2018155947A1 (ko)	2017-02-24	2018-08-30	재단법인 대구경북첨단의료산업진흥재단	혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
JOP20190281A1 (ar) *	2017-06-13	2019-12-02	Korea Res Inst Chemical Tech	مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
WO2019051084A1 (en)	2017-09-07	2019-03-14	Revolution Medicines, Inc.	SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
KR101992621B1 (ko)	2017-12-07	2019-09-27	주식회사 온코빅스	암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2019117813A1 (en) *	2017-12-15	2019-06-20	National University Of Singapore	Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
JP7085242B2 (ja) *	2017-12-21	2022-06-16	深▲チェン▼市塔吉瑞生物医薬有限公司	キナーゼ活性を阻害するためのアリールホスフィンオキシド
WO2019195753A1 (en)	2018-04-05	2019-10-10	Tolero Pharmaceuticals, Inc.	Axl kinase inhibitors and use of the same
WO2020076723A1 (en)	2018-10-08	2020-04-16	Revolution Medicines, Inc.	Shp2 inhibitor compositions for use in treating cancer
WO2020088390A1 (zh) *	2018-10-29	2020-05-07	江苏先声药业有限公司	作为***egfr抑制剂的嘧啶吡唑类化合物
WO2020147702A1 (en) *	2019-01-17	2020-07-23	Betta Pharmaceuticals Co., Ltd	Egfr inhibitors, compositions and methods thereof
KR20210146288A (ko)	2019-03-01	2021-12-03	레볼루션 메디슨즈, 인크.	이환식 헤테로사이클릴 화합물 및 이의 용도
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220028075A (ko)	2019-07-03	2022-03-08	스미토모 다이니폰 파마 온콜로지, 인크.	티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
JP2022553857A (ja)	2019-11-04	2022-12-26	レボリューションメディシンズインコーポレイテッド	Ｒａｓ阻害剤
US11608346B2 (en)	2019-11-04	2023-03-21	Revolution Medicines, Inc.	Ras inhibitors
MX2022005359A (es)	2019-11-04	2022-06-02	Revolution Medicines Inc	Inhibidores de ras.
MX2022005525A (es)	2019-11-08	2022-06-08	Revolution Medicines Inc	Compuestos de heteroarilo bicíclicos y usos de estos.
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4074697A4 (en)	2019-12-03	2024-01-03	Samjin Pharm Co Ltd	NOVEL ADAMANTANE DERIVATIVES AS FOCAL ADHESION KINASE INHIBITORS
TW202140011A (zh)	2020-01-07	2021-11-01	美商銳新醫藥公司	Shp2抑制劑給藥和治療癌症的方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CA3169286A1 (en) *	2020-02-25	2021-09-02	Dana-Farber Cancer Institute, Inc.	Potent and selective degraders of alk
MX2022016355A (es)	2020-06-18	2023-04-03	Revolution Medicines Inc	Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
IL301062A (en)	2020-09-03	2023-05-01	Revolution Medicines Inc	Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
TW202227460A (zh)	2020-09-15	2022-07-16	美商銳新醫藥公司	Ｒａｓ抑制劑
AU2021409816A1 (en)	2020-12-22	2023-07-06	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
EP4320153A1 (en)	2021-04-09	2024-02-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of anaplastic large cell lymphoma
KR20240017811A (ko)	2021-05-05	2024-02-08	레볼루션 메디슨즈, 인크.	암의 치료를 위한 ras 억제제
WO2022235864A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Ras inhibitors
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
TW202340214A (zh)	2021-12-17	2023-10-16	美商健臻公司	做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL129020C (is)	1964-12-15
US3432493A (en) *	1966-06-27	1969-03-11	Abbott Lab	Substituted sulfanilamides
US3367149A (en) *	1966-12-15	1968-02-06	Minnesota Mining & Mfg	Radiant white light source
JPS5490121A (en) *	1977-11-28	1979-07-17	Boettcher Barry	Neutral copper bonded body and antiinflaming agent
JPS5964558A (ja) *	1982-09-30	1984-04-12	三菱電機株式会社	耐熱軟質複合体の製造法
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
GB9622363D0 (en) *	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
ES2308821T3 (es) *	1997-12-15	2008-12-01	Astellas Pharma Inc.	Nuevos derivados de pirimidin-5-carboxamida.
TR200002760T2 (tr)	1998-03-27	2000-12-21	Janssen Pharmaceutica N.V.	HIV engelleyici pirimidin türevleri
WO2000012485A1 (en)	1998-08-29	2000-03-09	Astrazeneca Ab	Pyrimidine compounds
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
WO2000075113A1 (fr) *	1999-06-09	2000-12-14	Yamanouchi Pharmaceutical Co., Ltd.	Nouveaux derives carboxamide heterocycliques
JP4622047B2 (ja) *	1999-06-09	2011-02-02	アステラス製薬株式会社	新規なヘテロ環カルボキサミド誘導体
WO2001025220A1 (en)	1999-10-07	2001-04-12	Amgen Inc.	Triazine kinase inhibitors
AU2001237041B9 (en)	2000-02-17	2005-07-28	Amgen Inc.	Kinase inhibitors
US6376770B1 (en) *	2000-02-28	2002-04-23	Douglas Hyde	Quick connecting universal electrical box and wiring system
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
US20020132823A1 (en)	2001-01-17	2002-09-19	Jiahuai Han	Assay method
EP1406875B1 (en) *	2001-06-26	2013-07-31	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) *	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
ATE389638T1 (de) *	2001-11-01	2008-04-15	Janssen Pharmaceutica Nv	Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
WO2003066601A1 (en) *	2002-02-08	2003-08-14	Smithkline Beecham Corporation	Pyrimidine compounds
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
WO2003095448A1 (en) *	2002-05-06	2003-11-20	Bayer Pharmaceuticals Corporation	Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
CA2490888C (en) *	2002-06-28	2011-05-24	Yamanouchi Pharmaceutical Co., Ltd.	Diaminopyrimidinecarboxamide derivative
ATE451104T1 (de) *	2002-07-29	2009-12-15	Rigel Pharmaceuticals Inc	Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
JP5602333B2 (ja) *	2003-02-07	2014-10-08	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖ感染の予防のためのピリミジン誘導体
ATE433447T1 (de) *	2003-02-20	2009-06-15	Smithkline Beecham Corp	Pyrimiidinverbindungen
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
ATE413404T1 (de) *	2003-07-16	2008-11-15	Janssen Pharmaceutica Nv	Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
AU2004260738B2 (en) *	2003-07-16	2009-07-16	Janssen Pharmaceutica N.V.	Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
EP1663242B1 (en) *	2003-08-07	2011-04-27	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
SG145749A1 (en)	2003-08-15	2008-09-29	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) *	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
EP1663992A1 (en) *	2003-09-18	2006-06-07	Novartis AG	2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
CA2584295C (en)	2004-11-24	2014-08-26	Rigel Pharmaceuticals, Inc.	Spiro-2, 4-pyrimidinediamine compounds and their uses

2004
- 2004-08-13 SG SG200806063-4A patent/SG145749A1/en unknown
- 2004-08-13 PL PL10010291T patent/PL2287156T3/pl unknown
- 2004-08-13 BR BRPI0413616A patent/BRPI0413616B8/pt active IP Right Grant
- 2004-08-13 MX MXPA06001759A patent/MXPA06001759A/es active IP Right Grant
- 2004-08-13 KR KR1020067003056A patent/KR100904570B1/ko active Protection Beyond IP Right Term
- 2004-08-13 MY MYPI20043301A patent/MY147449A/en unknown
- 2004-08-13 WO PCT/EP2004/009099 patent/WO2005016894A1/en active Application Filing
- 2004-08-13 SI SI200432067T patent/SI2287156T1/sl unknown
- 2004-08-13 US US10/568,367 patent/US7893074B2/en active Active
- 2004-08-13 CA CA002533320A patent/CA2533320A1/en not_active Abandoned
- 2004-08-13 AU AU2004264382A patent/AU2004264382A1/en not_active Abandoned
- 2004-08-13 AT AT04764093T patent/ATE542801T1/de active
- 2004-08-13 PT PT100102912T patent/PT2287156E/pt unknown
- 2004-08-13 JP JP2006522998A patent/JP4607879B2/ja active Active
- 2004-08-13 RU RU2006107785/04A patent/RU2395500C2/ru active
- 2004-08-13 DK DK04764093.3T patent/DK1660458T3/da active
- 2004-08-13 EP EP10010291.2A patent/EP2287156B1/en active Active
- 2004-08-13 ES ES04764093T patent/ES2380206T3/es active Active
- 2004-08-13 PL PL04764093T patent/PL1660458T3/pl unknown
- 2004-08-13 PT PT04764093T patent/PT1660458E/pt unknown
- 2004-08-13 BR BR122019017579A patent/BR122019017579B8/pt active IP Right Grant
- 2004-08-13 SI SI200431849T patent/SI1660458T1/sl unknown
- 2004-08-13 EP EP04764093A patent/EP1660458B1/en active Active
- 2004-08-13 TW TW093124290A patent/TWI378923B/zh active
- 2004-08-13 DK DK10010291.2T patent/DK2287156T3/da active
- 2004-08-13 ES ES10010291T patent/ES2424881T3/es active Active
- 2004-08-13 NZ NZ585188A patent/NZ585188A/en not_active IP Right Cessation
- 2004-08-17 AR ARP040102945A patent/AR045458A1/es active IP Right Grant
2006
- 2006-01-12 IL IL173129A patent/IL173129A0/en unknown
- 2006-01-17 ZA ZA2006/00464A patent/ZA200600464B/en unknown
- 2006-02-14 TN TNP2006000052A patent/TNSN06052A1/en unknown
- 2006-02-15 EC EC2006006371A patent/ECSP066371A/es unknown
- 2006-02-17 MA MA28815A patent/MA27994A1/fr unknown
- 2006-02-20 CO CO06016492A patent/CO5680434A2/es active IP Right Grant
- 2006-03-13 IS IS8349A patent/IS2873B/is unknown
- 2006-03-15 NO NO20061214A patent/NO333306B1/no unknown
- 2006-11-07 HK HK06112236.3A patent/HK1091813A1/xx unknown
2008
- 2008-09-29 AU AU2008229685A patent/AU2008229685B2/en active Active
2010
- 2010-07-16 JP JP2010162177A patent/JP2010241830A/ja active Pending
2011
- 2011-01-04 US US12/984,519 patent/US20110098280A1/en not_active Abandoned
2012
- 2012-03-22 CY CY20121100300T patent/CY1112571T1/el unknown
- 2012-04-16 HR HRP20120335TT patent/HRP20120335T1/hr unknown
2013
- 2013-08-01 HR HRP20130724TT patent/HRP20130724T1/hr unknown
- 2013-08-13 CY CY20131100696T patent/CY1117015T1/el unknown

Also Published As

Publication number	Publication date
CA2533320A1 (en)	2006-02-24
RU2006107785A (ru)	2007-09-20
BR122019017579B1 (pt)	2020-08-11
AU2008229685B2 (en)	2011-07-28
TW200526598A (en)	2005-08-16
US20110098280A1 (en)	2011-04-28
BR122019017579B8 (pt)	2021-07-27
TWI378923B (en)	2012-12-11
TNSN06052A1 (en)	2007-10-03
MXPA06001759A (es)	2006-05-12
AU2008229685A1 (en)	2008-10-30
ES2424881T3 (es)	2013-10-09
AU2004264382A1 (en)	2005-02-24
CO5680434A2 (es)	2006-09-29
MA27994A1 (fr)	2006-07-03
ATE542801T1 (de)	2012-02-15
BRPI0413616B1 (pt)	2020-04-28
HK1091813A1 (en)	2007-01-26
CY1112571T1 (el)	2016-02-10
PL2287156T3 (pl)	2013-11-29
ES2380206T3 (es)	2012-05-09
EP2287156B1 (en)	2013-05-29
PL1660458T3 (pl)	2012-07-31
MY147449A (en)	2012-12-14
RU2395500C2 (ru)	2010-07-27
NO20061214L (no)	2006-05-15
CY1117015T1 (el)	2017-04-05
PT1660458E (pt)	2012-04-27
ZA200600464B (en)	2006-12-27
KR100904570B1 (ko)	2009-06-25
BRPI0413616A (pt)	2006-10-17
US20080132504A1 (en)	2008-06-05
IS2873B (is)	2014-03-15
ECSP066371A (es)	2006-08-30
SI2287156T1 (sl)	2013-09-30
SI1660458T1 (sl)	2012-05-31
EP1660458A1 (en)	2006-05-31
IS8349A (is)	2006-03-13
HRP20130724T1 (hr)	2013-10-11
JP2010241830A (ja)	2010-10-28
DK1660458T3 (da)	2012-05-07
SG145749A1 (en)	2008-09-29
EP2287156A1 (en)	2011-02-23
DK2287156T3 (da)	2013-08-26
NO333306B1 (no)	2013-04-29
PT2287156E (pt)	2013-08-26
EP1660458B1 (en)	2012-01-25
JP4607879B2 (ja)	2011-01-05
JP2007502260A (ja)	2007-02-08
WO2005016894A1 (en)	2005-02-24
NZ585188A (en)	2011-09-30
IL173129A0 (en)	2006-06-11
BRPI0413616B8 (pt)	2021-05-25
KR20060039938A (ko)	2006-05-09
US7893074B2 (en)	2011-02-22
AR045458A1 (es)	2005-10-26

Publication	Publication Date	Title
HRP20120335T1 (hr)	2012-05-31	2,4-pirimidindiamini korisni za liječenje neoplastičnih bolesti, upala i poremećaja imunološkog sustava
HRP20160852T1 (hr)	2016-09-23	Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
KR101311757B1 (ko)	2013-09-26	2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온
AU2005313348B2 (en)	2011-10-06	2,4 (4,6) pyrimidine derivatives
AU592569B2 (en)	1990-01-18	2-thio or oxo-4-aryl or heterocyclo-1,5 (2h)- pyrimidinedi-carboxylic acid diesters and 3-acyl-5- pyrimidinecarboxylic acids and esters
IL225883A (en)	2016-07-31	Heterocyclic compounds and their uses
KR20050057399A (ko)	2005-06-16	카나비노이드-ｃｂ1 수용체 리간드로서의1ｈ-1,2,4-트리아졸-3-카복스아미드 유도체
JP2020531481A (ja)	2020-11-05	エーテル化合物およびその使用
JP2005508336A5 (is)	2006-01-12
DE60025385T2 (de)	2006-08-24	2,4-diaminopyrimidinderivate als immunosuppressiva
WO2003099286A1 (en)	2003-12-04	Pyrrolotriazinone compounds and their use to treat diseases
TW200719890A (en)	2007-06-01	Bicyclic [3. 1. 0] heteroaryl amides as type i glycine transport inhibitors
EP3917916A1 (en)	2021-12-08	Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
CA2838885A1 (en)	2012-12-13	Pyrimido[4,5-d]pyrimidinyl compounds, pharmaceutical compositions and use thereof
CA2769421A1 (en)	2011-02-10	Viral replication inhibitors
CA2520465A1 (en)	2004-10-14	Bi-cyclic pyrimidine inhibitors of tgf.beta.
MY143578A (en)	2011-05-31	Piperazinediones as oxytocin receptor antagonists
BRPI0514738A (pt)	2008-06-24	derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
SG189499A1 (en)	2013-05-31	Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
TW200510429A (en)	2005-03-16	Heterocyclic MCHR1 antagonists
HRP20100250T1 (hr)	2010-06-30	Heterociklički kondenzirani spojevi upotrebljivi kao antidiuretski agensi
JP2021527098A (ja)	2021-10-11	縮合チオフェン化合物
US20090069341A1 (en)	2009-03-12	Inhibitors of hsp90
JP2020504716A5 (is)	2021-02-04
CZ413991A3 (en)	1993-01-13	Bicyclic compounds, their salts, solvates, hydrates and esters